TNP-470 (AGM-1470): mechanisms of action and early clinical development.
Castronovo
V
V
Metastasis Research Laboratory, University of Liège, Belgium.
Belotti
D
D
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002417:Cattle; D002478:Cells, Cultured; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003510:Cyclohexanes; D004359:Drug Therapy, Combination; D004730:Endothelium, Vascular / Q000187:drug effects; D006801:Humans; D008253:Macaca mulatta; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D018919:Neovascularization, Physiologic / Q000187:drug effects; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D051381:Rats; D012717:Sesquiterpenes / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000903:Antibiotics, Antineoplastic; D003510:Cyclohexanes; D012717:Sesquiterpenes; D000077609:O-(Chloroacetylcarbamoyl)fumagillol